Neurocrine Biosciences, Inc. (NBIX) Director Richard F. Pops Sells 5,500 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Richard F. Pops sold 5,500 shares of the business’s stock in a transaction on Monday, October 29th. The stock was sold at an average price of $107.13, for a total transaction of $589,215.00. Following the completion of the sale, the director now owns 37,759 shares of the company’s stock, valued at $4,045,121.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:NBIX opened at $106.29 on Wednesday. The firm has a market cap of $9.70 billion, a P/E ratio of -65.61, a P/E/G ratio of 34.46 and a beta of 0.55. Neurocrine Biosciences, Inc. has a one year low of $60.38 and a one year high of $126.98. The company has a quick ratio of 9.19, a current ratio of 9.19 and a debt-to-equity ratio of 1.00.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Tuesday, July 31st. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.11. The firm had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $84.11 million. Neurocrine Biosciences had a negative net margin of 16.07% and a negative return on equity of 14.22%. The business’s quarterly revenue was up 1428.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.68) EPS. As a group, analysts forecast that Neurocrine Biosciences, Inc. will post 0.15 earnings per share for the current fiscal year.



NBIX has been the subject of a number of analyst reports. Cantor Fitzgerald initiated coverage on shares of Neurocrine Biosciences in a research note on Wednesday, August 22nd. They issued an “overweight” rating and a $150.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $162.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, August 1st. Oppenheimer set a $128.00 price objective on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Tuesday, July 31st. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, July 27th. Finally, ICAP reduced their price objective on shares of Neurocrine Biosciences from $140.00 to $128.00 and set an “outperform” rating for the company in a research note on Tuesday, September 4th. One equities research analyst has rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $122.22.

A number of large investors have recently added to or reduced their stakes in NBIX. Meeder Asset Management Inc. raised its stake in Neurocrine Biosciences by 643.7% during the 2nd quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock valued at $110,000 after purchasing an additional 972 shares during the last quarter. TRUE Private Wealth Advisors acquired a new position in Neurocrine Biosciences during the 3rd quarter valued at $127,000. Steward Partners Investment Advisory LLC acquired a new position in Neurocrine Biosciences during the 3rd quarter valued at $127,000. Ladenburg Thalmann Financial Services Inc. raised its stake in Neurocrine Biosciences by 103.4% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,016 shares of the company’s stock valued at $167,000 after purchasing an additional 1,025 shares during the last quarter. Finally, Financial Architects Inc raised its stake in Neurocrine Biosciences by 283.7% during the 3rd quarter. Financial Architects Inc now owns 1,385 shares of the company’s stock valued at $170,000 after purchasing an additional 1,024 shares during the last quarter.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

See Also: Understanding each part of a balance sheet

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply